At least five ongoing phase III trials are investigating anti-PD-1 or anti-PD-L1 mAbs (pembrolizumab, nivolumab, durvalumab, atezolizumab, and toripalimab) with or without antiangiogenic agents as adjuvant therapy after surgery or thermic local ablation for localized HCC (Table 4). This evidence concerns the gene CD274 and hepatocellular carcinoma.